Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1634 • ACR Convergence 2020
Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?
Therese Posas-Mendoza¹, Cara McLeod¹, William Davis² and Robert Quinet², ¹Ochsner Medical Center, New Orleans, LA, ²Dept of Rheumatology, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease characterized by immune-overstimulation and a hyperinflammatory response resulting in cytokine storm and multi-organ failure.1 Secondary HLH…
Abstract Number: 1683 • ACR Convergence 2020
Ready or Not? Measuring Readiness for Transition to Adult Care in Adolescents with JIA & jSLE
Jeanine McColl¹, Teresa Semalulu¹, Arzoo Alam², Steffy Thomas², Julie Herrington³, Jan Willem Gorter², Tania Cellucci², Stephanie Garner², Liane Heale², Mark Matsos², Karen Beattie¹ and Michelle Batthish⁴, ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³The Canadian Arthritis Society, Hamilton, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: Transitioning from pediatric to adult care represents a particularly vulnerable period among patients with JIA and jSLE. The shift to adult care is often…
Abstract Number: 1795 • ACR Convergence 2020
Intracellular Homocysteine and Homocysteine Metabolites in Systemic Lupus Erythematosus (SLE)
George Stojan¹, Jessica Li¹, Amrita Raj², Maureen Kane³ and Michelle Petri⁴, ¹Johns Hopkins University, BALTIMORE, MD, ²Johns Hopkins University, Baltimore, ³University of Maryland School of Pharmacy, Baltimore, ⁴Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: In SLE, homocysteine has been shown to be a potentially modifiable, independent risk factor for stroke and thrombotic events. All previous epidemiological studies used…
Abstract Number: 1813 • ACR Convergence 2020
A Comprehensive Method to Study Environmental Chemicals in Serum in Patients with SLE
Cristina Lanata¹, Kim Taylor², James Hurst-Hopf¹, Laura Trupin¹, Patricia Katz³, Jinoos Yazdany¹, Maria Dall'Era⁴, Dimitri Abrahamsson¹, Lindsey Criswell⁵ and Roy Gerona¹, ¹UCSF, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³University of California, San Francisco, Novato, CA, ⁴Division of Rheumatology, University of California, San Francisco, CA, ⁵Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA
Background/Purpose: Environmental exposures may play a substantial role in the pathogenesis of Systemic Lupus Erythematosus (SLE), however it has been challenging to measure and capture…
Abstract Number: 1829 • ACR Convergence 2020
Lupus Disease Activity After Cessation of Anifrolumab Treatment During the Phase 2b MUSE Trial Follow-up Period
Richard Furie¹, Kenneth Kalunian², Joan Merrill³, Gabriel Abreu⁴ and Raj Tummala⁵, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, ²School of Health Sciences, University of California, La Jolla, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg
Background/Purpose: In the randomized, double-blind, phase 2b MUSE trial, anifrolumab reduced disease activity vs placebo across multiple endpoints in patients with moderately to severely active…
Abstract Number: 1847 • ACR Convergence 2020
Delayed and Immediate Release Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus
Hope Rainey¹, Kristy Bell¹, Violeta Rus², Daniel Wallace³, Claire Dykas¹, Mary Mora¹, Maggy Comberg¹ and Peter Lipsky¹, ¹AMPEL BioSolutions LLC., Charlottesville, VA, ²University of Maryland School of Medicine, Baltimore, MD, ³Cedars-Sinai Medical Center/UCLA, Los Angeles, CA
Background/Purpose: Morning stiffness and fatigue are common symptoms in patients with SLE. Increased cytokines and disturbed sleep patterns may contribute to morning symptoms and fatigue…
Abstract Number: 0250 • ACR Convergence 2020
Lupus Nephritis and Renal Outcomes in African-Americans: The Accelerating Medicines Partnership Cohort Experience
Andrea Fava¹, Jessica Li¹, Philip Carlucci², David Wofsy³, Judith James⁴, Chaim Putterman⁵, Betty Diamond⁶, Derek Fine⁷, Jose Monroy-Trujillo⁷, Kristin Haag⁷, Kristina Deonaraine⁸, The Accelerating Medicines Partnership in SLE Network⁹, William Apruzzese¹⁰, Jill Buyon¹¹ and Michelle Petri¹², ¹Johns Hopkins University, Baltimore, MD, ²New York University School of Medicine, New York, NY, ³University of California San Francisco, San Francisco, CA, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Northwell Health, Manhasset, NY, ⁷Johns Hopkins University, Baltimore, ⁸New York University School of Medicine, New York, ⁹Multiple Institutions, Multiple Cities, ¹⁰., Boston, ¹¹Department of Medicine, NYU School of Medicine, New York, NY, ¹²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: The Accelerating Medicines Partnership (AMP) will use multi-omics modalities including single cell RNA sequencing to understand lupus nephritis with the ultimate goal to devise…
Abstract Number: 0267 • ACR Convergence 2020
Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?
Beatriz Tejera Segura¹, Irene Altabás González², Iñigo Rúa-Figueroa³, Natalia Pérez Veiga⁴, Victor del Campo Pérez⁵, Alejandro Olivé-Marqués⁶, Maria Galindo-Izquierdo⁷, Jaime Calvo-Alén⁸, Juan Ovalles-Bonilla⁹, Antonio Fernandez-Nebro¹⁰, Raul Menor Almagro¹¹, Eva Tomero Muriel¹², N. Del-val-del-amo¹³, Maria Esther Uriarte¹⁴, VM Martínez Taboada¹⁵, Jose Luis Andreu Sanchez¹⁶, Alina Lucica Boteanu¹⁷, Francisco Javier Narváez¹⁸, A Morasat¹⁹, Carlos Montilla Morales²⁰, JM Senabre Gallego²¹, Blanca Hernández Cruz²², Mariano Andrés²³, Eva Salgado Pérez²⁴, Mercedes Freire-González²⁵, Sergio Ramon Machin Garcia¹, Clara Moriano²⁶, Lorena Expósito²⁷, Clara E. Perez-Velasquez²⁸, ML Velloso-Feijoo²⁹, Ana Paula Cacheda³⁰, Nuria Lozano Rivas³¹, Gema Bonilla³², Marta Arévalo³³, Inmaculada Jimenez³⁴, VE Quevedo-Vila³⁵, Francisco Manero-Ruiz³⁶, Paloma García de la Peña³⁷, TR Vázquez-Rodríguez³⁸, J Ibáñez-Ruan³⁹, Tatiana Cobo-Ibañez⁴⁰ and Jose Maria Pego-Reigosa⁴¹, ¹Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, ⁴Grupo IRIDIS, Universidad de Vigo, Vigo, Pontevedra, ⁵Hospital Universitario Meixoeiro, Vigo, Vigo, Pontevedra, Spain, ⁶Hospital Germans Trias i Pujol, Barcelona, Spain, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ⁹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁰University of Malaga, Malaga, Spain, ¹¹Hospital General Universitario de Jerez de la Frontera, Puerto De Santa Mar�a, Spain, ¹²Hospital Universitario de la Princesa, Madrid, Madrid, Spain, ¹³Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁴Hospital Universitario Donostia, San Sebastian, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁶Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹⁷PRINTO, Istituto Giannina Gaslini, Genova, Italy, ¹⁸Hospital Bellvitge, BARCELONA, Spain, ¹⁹Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ²⁰Hospital Universitario de Salamanca, Salamanca, Spain, ²¹Hospital Marina Baixa, Alicante, Spain, ²²Universidad de Sevilla, Sevilla, Spain, ²³Hospital General Universitario de Alicante, Alicante, Spain, ²⁴Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ²⁵CHU Coruña, Coruña, Spain, ²⁶Complejo Asistencial Universitario de León, León, Spain, ²⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²⁸Basurto University Hospital, Bilbao, Spain, ²⁹Hospital Universitario de Valme, Sevilla, Spain, ³⁰Hospital son LLátzer, Palma de Mallorca, Spain, ³¹Hospital Clínico Universitario Virgen de Arrixaca, Murcia, Spain, ³²Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ³³Hospital Universitari Parc Taulí I3PT, Sabadell, Spain, ³⁴Hospital Clínico San Ceciio Granada, Granada, Spain, ³⁵Hospital Comarcal de Monforte, Lugo, Spain, ³⁶Hospital Universitario Miguel Servet, Zaragoza, Spain, ³⁷Hospital HM, Madrid, Spain, ³⁸Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁹Hospital Povisa, Vigo, Pontevedra, Spain, ⁴⁰Hospital Infanta Sofia, Madrid, Spain, ⁴¹University Hospital of Vigo, Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: To describe the GI manifestations of SLE in the RELESSER (Registry of Systemic Lupus Erythematosus Patients of the Spanish Society of Rheumatology) cohort and…
Abstract Number: 0283 • ACR Convergence 2020
Genome-wide DNA Methylation Analysis in Lupus Keratinocytes Identifies Differential Methylation of Genes That Regulate Apoptosis
Grace Hile¹, Patrick Coit¹, Chang Zeng¹, Rachael Wasikowski², Alex Tsoi², Allison Billi², Johann Gudjonsson³, Amr Sawalha⁴ and J. Michelle Kahlenberg⁵, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann ARbor, ³University of Michigan, Ann ArborUniversity of Michigan, ⁴University of Pittsburgh, Pittsburgh, ⁵Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematous (CLE) is a disfiguring manifestation of systemic LE (SLE), and the pathogenesis remains unclear. However, epidermal regulation of skin inflammation and…
Abstract Number: 0301 • ACR Convergence 2020
Genetic Associations and Polygenic Risk Assessment in Incomplete Lupus Erythematosus
Matthew Slief¹, Jeremy Levin², Susan Macwana¹, Wade DeJager¹, Rebecka Bourn³, Swapan Nath³, Melissa Munroe⁴, Teresa Aberle¹, Patrick Gaffney⁵, Joan Merrill³, Judith James⁶ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²OU Medical Center, Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Patients with incomplete lupus erythematosus (ILE) have features of lupus, but have insufficient criteria for SLE classification. Some ILE patients transition to classified SLE,…
Abstract Number: 0496 • ACR Convergence 2020
A Role of Lipid-Peroxidation in Systemic Lupus Erythematosus-Associated Cardiovascular Disease
David Patrick¹, Justin van Beusecum¹, Michelle Ormseth², Leslie J. Crofford², Sean Davies³, Sergey Dikalov¹ and David Harrison¹, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville
Background/Purpose: In SLE, cardiovascular complications are a significant contributor to morbidity and death. Importantly, there is an increased prevalence of hypertension in SLE patients compared…
Abstract Number: 0617 • ACR Convergence 2020
Support Methodologies for African American Women with Lupus – Comparing Two Study’s Effects on Patient Activation
Ashley White¹, Trevor Faith¹, Aissatou Ba¹, Viswanathan Ramakrishnan², Hetlena Johnson³, Jillian Rose⁴, Clara Dismuke-Greer⁵, Jim Oates⁶, Leonard Egede⁷ and Edith Williams¹, ¹Medical University of South Carolina, Charleston, SC, ²medical university of south carolina, south carolina, ³LupusCSC, Columbia, SC, ⁴Hospital for Special Surgery, New York, ⁵Palo Alto VA, Palo Alto, CA, ⁶Medical University of South Carolina, Charleston, SC, Charleston, SC, ⁷Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory disease in which the immune system of affected individuals attacks their own healthy tissues. While pharmaceutical…
Abstract Number: 0850 • ACR Convergence 2020
What Does It Mean to Be a BICLA (BILAG-Based Composite Lupus Assessment) Responder? Post Hoc Analysis of the Phase 3 TULIP-1 and TULIP-2 Trials
Richard Furie¹, Eric Morand², Ian Bruce³, David Isenberg⁴, Ronald van Vollenhoven⁵, Gabriel Abreu⁶, Lilia Pineda⁷ and Raj Tummala⁷, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, ²Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ³Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴Centre for Rheumatology, University College London and Department of Rheumatology, University College Hospital, London, United Kingdom, ⁵Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals R&D, AstraZeneca, Gaithersburg
Background/Purpose: BICLA is a validated composite global measure of SLE disease activity that incorporates BILAG, an instrument that distinguishes between partial and complete improvement. BICLA…
Abstract Number: 0869 • ACR Convergence 2020
Retinal Toxicity in a Multinational Inception Cohort of Systemic Lupus Patients on Hydroxychloroquine
Celline Almeida-Brasil¹, John Hanly², Murray Urowitz³, Ann Clarke⁴, Rosalind Ramsey-Goldman⁵, Caroline Gordon⁶, Michelle Petri⁷, Ellen M Ginzler⁸, Daniel J Wallace⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Díaz¹¹, Mary Ann Dooley¹², Christine A. Peschken¹³, David Isenberg¹⁴, Anisur Rahman¹⁴, Susan Manzi¹⁵, Søren Jacobsen¹⁶, S. Sam Lim¹⁷, Ronald Van Vollenhoven¹⁸, Ola Nived¹⁹, Andreas Jönsen¹⁹, Diane Kamen²⁰, Cynthia Aranow²¹, Guillermo Ruiz-Irastorza²², Jorge Sanchez-Guerrero²³, Dafna Gladman²⁴, Paul Fortin²⁵, Graciela Alarcón²⁶, Joan Merrill²⁷, Kenneth Kalunian²⁸, Manuel Ramos-Casals²⁹, Kristjan Steinsson³⁰, Asad Zoma³¹, Anca Askanase³², Munther Khamashta³³, Ian Bruce³⁴, Murat Inanc³⁵ and Sasha Bernatsky³⁶, ¹McGill University, Montreal, Canada, ²QEII Health Sciences Centre, Halifax, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Calgary, Calgary, Canada, ⁵Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶University of Birmingham, Birmingham, England, United Kingdom, ⁷Johns Hopkins University School of Medicine, Baltimore, ⁸SUNY Downstate Health Sciences University, Brooklyn, ⁹Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹²UNC Health, Chapel Hil, ¹³University of Manitoba, Winnipeg, Canada, ¹⁴University College London, London, United Kingdom, ¹⁵Temple University, Philadelphia, ¹⁶University of Copenhagen, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸University of Amsterdam, Amsterdam, Netherlands, ¹⁹Lund University, Lund, Sweden, ²⁰Medical University of South Carolina, Charleston, SC, ²¹Feinstein Institutes for Medical Research, Manhasset, NY, ²²Hospital Universitario Cruces, Barakaldo, Spain, ²³University of Toronto, Toronto, Canada, ²⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²⁵CHU de Quebec - Universite Laval, Quebec, Canada, ²⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁷New York University, New York, ²⁸University of California San Diego, La Jolla, CA, ²⁹University of Barcelona, Barcelona, Spain, ³⁰Reykjavik University, Reykjavik, Iceland, ³¹University of Glasgow, Glasgow, United Kingdom, ³²Columbia University College of Physicians & Surgeons, New York, NY, ³³King's College London, London, United Kingdom, ³⁴The University of Manchester, Manchester, United Kingdom, ³⁵Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³⁶The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Despite the beneficial effects of hydroxychloroquine (HCQ) in systemic lupus erythematosus (SLE), retinal toxicity is a concern. Factors associated with retinal toxicity have been…
Abstract Number: 0985 • ACR Convergence 2020
Early and Sustained Reduction in Severity of Skin Disease with Anifrolumab Treatment in Patients with Active SLE Measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): Pooled Data from 2 Phase 3 Studies
Victoria Werth¹, Richard Furie², Eric Morand³, J. Michelle Kahlenberg⁴, Rubana Kalyani⁵, Gabriel Abreu⁶, Lilia Pineda⁵ and Raj Tummala⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, ³Monash University, Melbourne, Australia, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Up to 85% of patients with SLE experience skin disease.1 The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated index…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].